1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.2.1. Research Assumptions
1.2.2. Project Methodology
1.2.3. Forecast Methodology
1.2.4. Robust Quality Control
1.2.5. Key Considerations
1.2.5.1. Demographics
1.2.5.2. Economic Factors
1.2.5.3. Government Regulations
1.2.5.4. Supply Chain
1.2.5.5. COVID Impact / Related Factors
1.2.5.6. Market Access
1.2.5.7. Healthcare Policies
1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines
3. INTRODUCTION
3 Introduction
3.1. Chapter Overview
3.2. Overview of Biologics
3.2.1. Types of Biologics
3.3. Overview of Contract Research Organizations (CROs)
3.4. Evolution of CROs
3.5. Classification of CROs
3.6. Services Offered by CROs
3.7. Advantages of Outsourcing Operations to CROs
3.8. Risks Associated with Outsourcing Operations to CROs
4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Biologics Research
4.3. Models of Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Model
4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach
4.5. Selecting a CRO Partner
4.5.1. Key Considerations for Outsourcing Biologics-related Operations
4.6. Role of CROs in the Drug Development Process
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services
4.7. Conclusion
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Biopharmaceutical CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
5.2.2. Analysis by Scale of Operation
5.3. Preclinical Biopharmaceutical CROs
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Biologic
5.3.5. Analysis by Type of Services Offered
5.4. Clinical Biopharmaceutical CROs
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Analysis by Type of Biologics
5.4.5. Analysis by Type of Services Offered
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Biocon
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Services Portfolio
6.2.4. Future Outlook
6.3. Covance
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Financial Information
6.3.4. Future Outlook
6.4. ICON
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Future Outlook
6.5. Medpace
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Future Outlook
6.6. Pharmaron
6.6.1. Company Overview
6.6.2. Services Portfolio
6.6.3. Future Outlook
6.7. PPD
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Financial Information
6.7.4. Future Outlook
6.8. PRA Health Sciences
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Service Portfolio
6.8.4. Future Outlook
6.9. Syneos Health
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Services Portfolio
6.9.4. Future Outlook
6.10. Vimta Labs
6.10.1. Company Overview
6.10.2. Services Portfolio
6.10.3. Financial Information
6.10.4. Future Outlook
6.11. WuXi AppTec
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Service Portfolio
6.11.4. Future Outlook
7. BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Peer Group I
7.3.2. Peer Group II
7.3.3. Peer Group III
7.3.4. Peer Group IV
7.3.5. Peer Group V
7.3.6. Peer Group VI
7.3.7. Peer Group VII
7.3.8. Peer Group VIII
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Biopharmaceutical CROs: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership Model
8.3.2.1. Analysis by Year of Partnership and Type of Partnership Model
8.3.3. Most Active Players: Analysis by Number of Partnerships
8.3.4. Analysis by Scale of Operation
8.3.5. Analysis by Geography
8.3.5.1. Country-wise Analysis
8.3.5.2. Intercontinental and Intracontinental Agreements
9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Biopharmaceutical CROs: Mergers and Acquisitions
9.3.1. Analysis by Year of Acquisition
9.3.2. Analysis by Type of Collaboration
9.3.3. Analysis by Geography
9.3.3.1. Continent-wise Distribution
9.3.3.2. Country-wise Distribution
9.3.4. Ownership Change Matrix
9.3.5. Most Active Acquirers: Analysis by Number of Acquisitions
9.4. Distribution by Key Value Drivers
9.4.1. Analysis by Key Value Drivers
9.4.2. Analysis by Key Value Drivers and Year of Acquisitions
9.5. Valuation Analysis: Acquisition Deal Multiples
10. ATTRACTIVENESS COMPETATIVENESS MATRIX
10.1. Chapter Overview
10.2. AC Matrix: Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment
10.3. Analytical Methodology
10.4. AC Matrix: Contract Manufacturing Scenario in North America
10.5. AC Matrix: Contract Manufacturing Scenario in Europe
10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Biopharmaceutical CROs Market
11.3.1. Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
11.3.2. Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
11.3.3. Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
11.3.4. Global Biopharmaceutical CROs Market: Distribution by Geography
11.4. Biopharmaceutical CROs Market in North America
11.4.1. Biopharmaceutical CROs Market in North America: Distribution by Therapeutic Area
11.4.1.1. Biopharmaceutical CROs Market for Oncological Disorders in North America, Till 2035
11.4.1.2. Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Till 2035
11.4.1.3. Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Till 2035
11.4.1.4. Biopharmaceutical CROs Market for Neurological Disorders in North America, Till 2035
11.4.1.5. Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Till 2035
11.4.2. Biopharmaceutical CROs Market in North America: Distribution by Scale of Operation
11.4.2.1. Biopharmaceutical CROs Market for Preclinical Operations in North America, Till 2035
11.4.2.2. Biopharmaceutical CROs Market for Clinical Operations in North America, Till 2035
11.5. Biopharmaceutical CRO Services Market in Europe
11.5.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Europe
11.5.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Europe, Till 2035
11.5.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Europe, Till 2035
11.5.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Europe, Till 2035
11.5.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Europe, Till 2035
11.5.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Europe, Till 2035
11.5.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Europe
11.5.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Europe, Till 2035
11.5.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Europe, Till 2035
11.6. Biopharmaceutical CRO Services Market in Asia-Pacific
11.6.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Asia-Pacific
11.6.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Asia-Pacific, Till 2035
11.6.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Asia-Pacific, Till 2035
11.6.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Asia-Pacific, Till 2035
11.6.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Asia-Pacific, Till 2035
11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Asia-Pacific, Till 2035
11.6.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Asia-Pacific
11.6.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Asia-Pacific, Till 2035
11.6.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Asia-Pacific, Till 2035
11.7. Biopharmaceutical CRO Services Market in Latin America
11.8. Biopharmaceutical CRO Services Market in Middle East North America
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors
LIST OF FIGURES
Figure 3.1 Global Age-Standardized Incidence Rates for Cancer, 2018 (per 100,000 Individuals)
Figure 3.1 Mechanism of Immunotherapies
Figure 3.3 Immune Checkpoint Targets
Figure 4.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Phase of Development
Figure 4.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Immune Checkpoint
Figure 4.3 Next Generation Target Immune Checkpoint Inhibitors and Stimulators: Distribution by Highest Phase of Development
Figure 4.4 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Mechanism of Action
Figure 4.5 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Modality
Figure 4.6 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Route of Administration
Figure 4.7 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Oncological Indications
Figure 4.8 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Non-Oncological Indications
Figure 4.9 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Area
Figure 4.10 Popular Oncological Indication(s): Distribution by Target Immune Checkpoints
Figure 4.11 Popular Non-Oncological Indication(s): Distribution by Target Immune Checkpoints
Figure 4.12 Popular Disease Indication(s): Distribution by Target Immune Checkpoint in Highest Phase of Development
Figure 4.13 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Year of Establishment
Figure 4.14 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Company Size and Geographical Location
Figure 4.15 Leading Developer Companies: Distribution by Number of Pipeline Therapies
Figure 4.16 Popular Targets: Distribution by Number of Developers
Figure 4.17 World Map Representation: Analysis by Geography
Figure 5.1 Immune Checkpoint Inhibitors for CD47: Distribution by Phase of Development
Figure 5.2 Immune Checkpoint Inhibitors for CD47: Distribution by Therapeutic Modality
Figure 5.3 Immune Checkpoint Inhibitors for CD47: Distribution by Route of Administration
Figure 5.4 Immune Checkpoint Inhibitors for CD47: Distribution by Target Disease Indication
Figure 5.5 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Year of Establishment
Figure 5.6 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Company Size and Geographical Location
Figure 5.7 Leading Developers: Distribution by Number of Pipeline Therapies for CD47
Figure 5.8 World Map Representation: Distribution by Geography
Figure 6.1 Immune Checkpoint Stimulators for 4-1BB: Distribution by Phase of Development
Figure 6.2 Immune Checkpoint Stimulators for 4-1BB: Distribution by Therapeutic Modality
Figure 6.3 Immune Checkpoint Stimulators for 4-1BB: Distribution by Route of Administration
Figure 6.4 Immune Checkpoint Stimulators for 4-1BB: Distribution by Target Disease Indication
Figure 6.5 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Year of Establishment
Figure 6.6 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Company Size and Geographical Location
Figure 6.7 Leading Developers: Distribution by Number of Therapies for 4-1BB
Figure 6.8 World Map Representation: Distribution by Geography
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Since 2010
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.6 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.9 Leading Players: Distribution by Number of Registered Trials
Figure 7.10 Word Cloud Analysis: Distribution by Focus Areas
Figure 7.11 Clinical Trial Analysis: Distribution by Target Immune Checkpoint
Figure 7.12 Clinical Trial Analysis: Distribution by Target Immune Checkpoint and Trial Registration Year
Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.14 Popular Indication(s): Analysis by Number of Registered Trials
Figure 7.15 Clinical Trial Analysis: Phase-Wise Distribution of Most Popular Indications
Figure 7.16 Popular Interventions: Analysis by Number of Number of Registered Trials
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 8.1 Bristol-Myers Squibb: Annual Revenues, Since 2019 (USD Billion)
Figure 8.2 GlaxoSmithKline: Annual Revenues, Since 2019 (USD Billion)
Figure 8.3 Incyte: Annual Revenues, Since 2019 (USD Billion)
Figure 8.4 Novartis: Annual Revenues, Since 2019 (USD Billion)
Figure 9.1 Grant Analysis: Distribution by Year of Grant Award, Since 2016
Figure 9.2 Grant Analysis: Distribution by Amount Awarded (USD Million), Since 2019
Figure 9.3 Grant Analysis: Distribution by Administering Institute Center
Figure 9.4 Grant Analysis: Distribution by Funding Institute Center
Figure 9.5 Grant Analysis: Distribution by Support Period
Figure 9.6 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 9.7 Grant Analysis: Distribution by Type of Grant Application
Figure 9.8 Grant Analysis: Distribution by Purpose of Grant Award
Figure 9.9 Grant Analysis: Distribution by Grant Mechanism
Figure 9.10 Word Cloud: Emerging Focus Areas
Figure 9.11 Popular Target Immune Checkpoints: Distribution by Number of Grants
Figure 9.12 Grant Analysis: Distribution of Grant Amount Awarded by Target Immune Checkpoints (USD Million)
Figure 9.13 Grant Analysis: Distribution by Study Section Involved
Figure 9.14 Popular NIH Departments: Distribution by Number of Grants
Figure 9.15 Grant Analysis: Distribution by Types of Recipient Organizations
Figure 9.16 Prominent Program Officers: Distribution by Number of Grants
Figure 9.17 Popular Recipient Organizations: Distribution by Number of Grants
Figure 9.18 Grant Analysis: Distribution by Recipient Organizations
Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2017
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership Since 2017
Figure 10.4. Partnerships and Collaborations: Distribution by Number of Partnerships and Target Immune Checkpoint
Figure 10.5. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.6. Partnerships and Collaborations: Distribution Type of Partnership and Type of Partner
Figure 10.7. Partnerships and Collaborations: Most Active Players
Figure 10.8. Partnerships and Collaborations: Regional Distribution
Figure 10.9. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1. Target Competitiveness Analysis: Four-Dimensional Bubble Analysis
Figure 11.2. Target Competitiveness Analysis: Five-Dimensional Spider Web Analysis
Figure 12.1. Big Pharma Players: Logo Landscape
Figure 12.2. Big Pharma Players: Analysis by Number of Initiatives
Figure 12.3. Big Pharma Players: Analysis by Number of Unique Targets
Figure 12.4. Big Pharma Players: Analysis by Product Development Strategy
Figure 12.5. Big Pharma Players: Heat Map Analysis by Target Immune Checkpoint
Figure 12.6. Big Pharma Players: Analysis by Product Development Strategy across Target Immune Checkpoint
Figure 12.7. Heat Map Representation: Distribution of Big Pharma Initiatives Across Target Immune Checkpoints and Highest Stage of Development
Figure 12.8. Grid Representation: Analysis by Product Development and Target Immune Checkpoint
Figure 12.9. Big Pharma Players: Analysis by Type of Intervention
Figure 12.10. Heat Map Representation: Big Pharma Initiatives Focused on Oncological Indications
Figure 12.11. Heat Map Representation: Big Pharma Initiatives Focused on Non-Oncological Indications
Figure 12.12. Heat Map Representation: Distribution of Big Pharma Initiatives Across Target Immune Checkpoints and Indication
Figure 13.1 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, Till 2030 (USD Million)
Figure 13.2 DARZALEX® Sales Forecast: Till 2030 (USD Million)
Figure 13.3 SAR650984 Sales Forecast: Till 2030 (USD Million)
Figure 13.4 RRx-001 Sales Forecast: Till 2030 (USD Million)
Figure 13.5 GSK3359609 Sales Forecast: Till 2030 (USD Million)
Figure 13.6 Enoblituzumab Sales Forecast: Till 2030 (USD Million)
Figure 13.7 Omburtamab Sales Forecast:Till 2030 (USD Million)
Figure 13.8 APX005M Sales Forecast: Till 2030 (USD Million)
Figure 13.9 BI 655064 Sales Forecast: Till 2030 (USD Million)
Figure 13.10 BMS-986015 Sales Forecast: Till 2030 (USD Million)
Figure 13.11 CFZ533 Sales Forecast: Till 2030 (USD Million)
Figure 13.12 GBR 830 Sales Forecast: 2024: 2030 (USD Million)
Figure 13.13 KHK4083 Sales Forecast: Till 2030 (USD Million)
Figure 13.14 LAG525 Sales Forecast: Till 2030 (USD Million)
Figure 13.15 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region (USD Million)
Figure 13.16 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, Till 2030 (USD Million)
Figure 13.17 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in UK, Till 2030 (USD Million)
Figure 13.18 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Germany, Till 2030 (USD Million)
Figure 13.19 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in France, Till 2030 (USD Million)
Figure 13.20 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Italy, Till 2030 (USD Million)
Figure 13.21 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Spain, Till 2030 (USD Million)
Figure 13.22 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Australia, Till 2030 (USD Million)
Figure 13.23 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Japan, Till 2030 (USD Million)
Figure 13.24 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in India, Till 2030 (USD Million)
Figure 13.25 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Therapeutic Area (USD Million)
Figure 13.26 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Oncological Indications, Till 2030 (USD Million)
Figure 13.27 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-Oncological Indications, Till 2030 (USD Million)
Figure 13.28 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Atopic Dermatitis, Till 2030 (USD Million)
Figure 13.29 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Breast Cancer, Till 2030 (USD Million)
Figure 13.30 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Chronic Lymphocytic Leukemia, Till 2030 (USD Million)
Figure 13.31 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, Till 2030 (USD Million)
Figure 13.32 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, Till 2030 (USD Million)
Figure 13.33 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, Till 2030 (USD Million)
Figure 13.34 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lupus Nephritis, Till 2030 (USD Million)
Figure 13.35 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, Till 2030 (USD Million)
Figure 13.36 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Multiple Myeloma, Till 2030 (USD Million)
Figure 13.37 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, Till 2030 (USD Million)
Figure 13.38 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Primary Sjogren’s Syndrome, Till 2030 (USD Million)
Figure 13.39 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Ulcerative colitis, Till 2030 (USD Million)
Figure 13.40 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint, 2027 and 2030
Figure 13.41 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, Till 2030 (USD Million)
Figure 13.42 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, Till 2030 (USD Million)
Figure 13.43 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, Till 2030 (USD Million)
Figure 13.44 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, Till 2030 (USD Million)
Figure 13.45 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, Till 2030 (USD Million)
Figure 13.46 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for KIR Targeting Therapies, Till 2030 (USD Million)
Figure 13.47 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for LAG-3 Targeting Therapies, Till 2030 (USD Million)
Figure 13.48 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for OX40 Targeting Therapies, Till 2030 (USD Million)
Figure 13.49 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action, 2025 and 2030
Figure 13.50 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, Till 2030 (USD Million)
Figure 13.51 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, Till 2030 (USD Million)
Figure 13.52 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality (USD Million)
Figure 13.53 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibody, Till 2030 (USD Million)
Figure 13.54 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, Till 2030 (USD Million)
Figure 13.55 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy, 2027 and 2030 (USD Million)
Figure 13.56 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, Till 2030 (USD Million)
Figure 13.57 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, Till 2030 (USD Million)
Figure 13.58 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, Till 2030 (USD Million)
Figure 13.59 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration, Till 2030 (USD Million)
Figure 13.60 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, Till 2030 (USD Million)
Figure 13.61 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, Till 2030 (USD Million)
Figure 13.62 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, Till 2030 (USD Million)
LIST OF TABLES
Table 3.1 Types of Immunotherapies and Associated Mechanisms of Action
Table 3.2 First Generation Immune Checkpoint Therapies
Table 4.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Target Immune Checkpoints
Table 4.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
Table 4.3 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
Table 5.1 Immune Checkpoint Inhibitors for CD47: Development Pipeline
Table 5.2 Immune Checkpoint Inhibitors for CD47: List of Therapy Developers
Table 6.1 Immune Checkpoint Stimulators for 4-1BB: Development Pipeline
Table 6.2 Immune Checkpoint Stimulators for 4-1BB: List of Therapy Developers
Table 8.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Companies Profiled
Table 8.2 Bristol- Myers Squibb: Company Snapshot
Table 8.3 Drug Profile: BMS-986213
Table 8.4 Drug Profile: BMS-986016
Table 8.5 Drug Profile: BMS-986258
Table 8.6 Drug Profile: BMS-986207
Table 8.7 Drug Profile: BMS-986179
Table 8.8 Drug Profile: BMS-663513
Table 8.9 Drug Profile: BMS-986178
Table 8.10 Drug Profile: BMS-936561
Table 8.11 Bristol-Myers Squibb: Future Outlook
Table 8.12 GlaxoSmithKline: Company Snapshot
Table 8.13 Drug Profile: GSK3359609
Table 8.14 Drug Profile: GSK2831781
Table 8.15 Drug Profile: GSK3174998
Table 8.16 Drug Profile: TSR-022
Table 8.17 Drug Profile: TSR-033
Table 8.18 Drug Profile: TSR-075
Table 8.19 GlaxoSmithKline: Future Outlook
Table 8.20 Incyte: Company Snapshot
Table 8.21 Drug Profile: INCB024360
Table 8.22 Drug Profile: INCB001158
Table 8.23 Drug Profile: INCAGN01876
Table 8.24 Drug Profile: INCAGN1876
Table 8.25 Drug Profile: INCAGN1949
Table 8.26 Drug Profile: MCLA-145
Table 8.27 Drug Profile: INCAGN2385
Table 8.28 Drug Profile: INCAGN2390
Table 8.29 Incyte: Future Outlook
Table 8.30 Novartis: Company Snapshot
Table 8.31 Drug Profile: CFZ533
Table 8.32 Drug Profile: MBG453
Table 8.33 Drug Profile: LAG525
Table 8.34 Drug Profile: GWN323
Table 8.35 Drug Profile: NZV930
Table 8.36 Novartis: Future Outlook
Table 8.37 Trillium Therapeutics: Company Snapshot
Table 8.38 Drug Profile: TTI-622-01
Table 8.39 Drug Profile: TTI-622-01
Table 8.40 Drug Profile: TTI-622
Table 8.41 Drug Profile: CD200 Monoclonal Antibodies
Table 8.42 Trillium Therapeutics: Future Outlook
Table 10.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
Table 13.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Forecasted Drug Candidates
Table 13.2 Darzalex: Target Patient Population (USD Million)
Table 13.3 SAR650984: Target Patient Population (USD Million)
Table 13.4 RRx-001: Target Patient Population (USD Million)
Table 13.5 GSK3359609: Target Patient Population (USD Million)
Table 13.6 Enoblituzumab: Target Patient Population (USD Million)
Table 13.7 Omburtamab: Target Patient Population (USD Million)
Table 13.8 APX005M: Target Patient Population (USD Million)
Table 13.9 BI 655064: Target Patient Population (USD Million)
Table 13.10 BMS-986015: Target Patient Population (USD Million)
Table 13.11 CFZ533: Target Patient Population (USD Million)
Table 13.12 GBR 830: Target Patient Population (USD Million)
Table 13.13 KHK4083: Target Patient Population (USD Million)
Table 13.13 LAG525: Target Patient Population (USD Million)
Table 14.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Summary of the Competitive Insights
Table 15.1 IGM Biosciences: Key Highlights
Table 16.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Phase of Development
Table 16.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Immune Checkpoint
Table 16.3 Next Generation Target Immune Checkpoint Inhibitors and Stimulators: Distribution by Highest Phase of Development
Table 16.4 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Mechanism of Action
Table 16.5 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Modality
Table 16.6 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Route of Administration
Table 16.7 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Oncological Indications
Table 16.8 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Non-Oncological Indications
Table 16.9 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Area
Table 16.10 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Year of Establishment
Table 16.11 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Company Size and Location of Headquarters
Table 16.12 Leading Developer Companies: Distribution by Number of Pipeline Therapies
Table 16.13 Leading Targets: Distribution by Number of Developers
Table 16.14 Word Map Representation: Distribution by Geography
Table 16.15 Immune Checkpoint Stimulators for CD47: Distribution by Phase of Development
Table 16.16 Immune Checkpoint Inhibitors for CD47: Distribution by Therapeutic Modality
Table 16.17 Immune Checkpoint Inhibitors for CD47: Distribution by Target Disease Indication
Table 16.18 Immune Checkpoint Inhibitors for CD47: Distribution by Route of Administration
Table 16.19 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Year of Establishment
Table 16.20 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Company Size
Table 16.21 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Location
Table 16.22 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Location
Table 16.23 Leading Developers: Distribution by Number of Pipeline Therapies for CD47
Table 16.24 Immune Checkpoint Stimulators for 4-1BB: Distribution by Phase of Development
Table 16.25 Immune Checkpoint Stimulators for 4-1BB: Distribution by Therapeutic Modality
Table 16.26 Immune Checkpoint Stimulators for 4-1BB: Distribution by Target Disease Indication
Table 16.27 Immune Checkpoint Stimulators for 4-1BB: Distribution by Route of Administration
Table 16.28 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Year of Establishment
Table 16.29 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Location
Table 16.30 Leading Developers: Distribution by Number of Pipeline Therapies for 4-1BB
Table 16.31 Clinical Trial Analysis: Distribution by Trial Status
Table 16.32 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Since 2010
Table 16.33 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patient’s Enrolled
Table 16.34 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 16.35 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Table 16.36 Clinical Trial Analysis: Distribution by Study Design
Table 16.37 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.38 Leading Players: Distribution by Number of Registered Trials
Table 16.39 Clinical Trial Analysis: Distribution by Target Immune Checkpoint
Table 16.40 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 16.41 Popular Indications: Distribution by Registered Trials
Table 16.42 Clinical Trial Analysis: Phase-Wise Distribution of Most Popular Indications
Table 16.43 Popular Interventions: Analysis by Number of Registered Trials
Table 16.44 Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table 16.45 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 16.46 Bristol-Myers Squibb: Annual Revenues, Since 2015 (USD Billion)
Table 16.47 GlaxoSmithKline: Annual Revenues, Since 2015 (USD Billion)
Table 16.48 Incyte: Annual Revenues, Since 2015 (USD Billion)
Table 16.49 Novartis: Annual Revenues, Since 2015 (USD Billion)
Table 16.50 Grant Analysis: Distribution by Year of Grant Award, Since 2016
Table 16.51 Grant Analysis: Distribution by Amount Awarded (USD Million), Since 2016
Table 16.52 Grant Analysis: Distribution by Administering Institute Center
Table 16.53 Grant Analysis: Distribution by Funding Institute Center
Table 16.54 Grant Analysis: Distribution by Support Period
Table 16.55 Grant Analysis: Distribution by Type of Grant Application
Table 16.56 Grant Analysis: Distribution by Purpose of Grant Award
Table 16.57 Grant Analysis: Distribution by Grant Mechanism Popular Target Immune Checkpoints: Distribution by Number of Grants
Table 16.58 Grant Analysis: Distribution of Grant Amount Awarded by Target Immune Checkpoints
Table 16.59 Grant Analysis: Distribution by Study Section Involved
Table 16.60 Grant Analysis: Distribution by Types of Recipient Organizations
Table 16.61 Popular NIH Departments: Distribution by Number of Grants
Table 16.62 Prominent Program Officers: Distribution by Number of Grants
Table 16.63 Grant Analysis: Distribution by Recipient Organizations
Table 16.64 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2017
Table 16.65 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.66 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, Since2017
Table 16.67 Partnerships and Collaborations: Distribution by Target Immune Checkpoint
Table 16.68 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 16.69 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Table 16.70 Most Active Players: Distribution by Number of Partnerships
Table 16.71 Partnership and Collaborations: Regional Distribution
Table 16.72 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 16.73 Big Pharma Players: Distribution by Number of Initiatives
Table 16.74 Big Pharma Plyers: Analysis by Number of Unique Targets
Table 16.75 Big Pharma Plyers: Analysis by Product Development Strategy
Table 16.76 Big Pharma Players: Analysis by Product Development Strategy across Target Immune Checkpoint
Table 16.77 Big Pharma Players: Analysis by Type of Intervention
Table 16.78 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.79 DARZALEX: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.80 SAR650984: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.81 RRx-001: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.82 GSK3359609: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.83 Enoblituzumab: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.84 Omburtamb: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.85 APXOO5M: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.86 BI 655064: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.87 BMS-986015: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.88 CFZ533: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.89 GBR 830: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.90 KHK4083: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.91 LAG525: Sales Forecast, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.92 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region (USD Million)
Table 16.93 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.94 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in UK, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.95 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in EU4, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.96 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Germany, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.97 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in France, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.98 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Italy, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.99 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Spain, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.100 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Australia, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.101 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Japan, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.102 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in India, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.103 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Therapeutic Area (USD Million)
Table 16.104 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Oncological Disorders, Till 2030 (USD Million)
Table 16.105 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-oncological Disorders, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.106 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Atopic Dermatitis, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.107 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Breast Cancer, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.108 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Chronic Lymphocytic Leukemia, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.109 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.110 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.111 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.112 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lupus Nephritis, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.113 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.114 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Multiple Myeloma, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.115 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.116 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Primary Sjogren’s Syndrome, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.117 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Ulcerative Colitis, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.118 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint, 2027 and 2030 (USD Million)
Table 16.119 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.120 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.121 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.122 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.123 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.124 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for KIR Targeting Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.125 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for LAG-3 Targeting Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.126 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for OX40 Targeting Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.127 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action (USD Million)
Table 16.128 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.129 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.130 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality, 2025 and 2030 (USD Million)
Table 16.131 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibody, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.132 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecules, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.133 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy, 2027 and 2030 (USD Million)
Table 16.134 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.135 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.136 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.137 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration, 2027 and 2020 (USD Million)
Table 16.138 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.139 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.140 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, Till 2030: Conservative, Base and Optimistic Scenarios (USD Million)
